Emergency Response Cart May Solve Ventilator Workflow Issues

Midwest Products & Engineering Announces Launch

Emergency Response Cart may solve ventilator workflow issues related to the urgent treatment of COVID-19 patients. The cart was launched today by Midwest Products & Engineering (MPE).

The largest custom medical cart manufacturer in the United States, MPE received valuable input from numerous healthcare partners of the immediate need for a medical cart that could support various ventilators and their respective workflows.

MPE went from napkin sketch to market-ready product in only 10 days. The result is a COVID-19 ventilator workflow cart that is durable yet lightweight for high demand ICU and Critical Care environments. Workflow compatibility is achieved with an all-inclusive device shelf, basket, total lock medical-grade casters, and three mounting rails to hold the ventilator circuit arm, humidifier, and other necessary equipment. It can also carry oxygen tanks for the transport of a ventilated patient or for use in locations that lack an oxygen supply. Made in the USA, ships fully assembled for rapid deployment and immediate field use.

Hank Kohl, MPE President, and CEO note the entire organization has rallied to meet the challenges that manufacturers of medical equipment are facing to meet the urgent needs of healthcare professionals fighting COVID-19.

“We have resolved to be part of the solution,” Mr. Kohl said. “From initial concepts to full volume production, MPE has delivered a medical cart optimized to support over 90% of ventilators. In addition, we are working with all of the major medical distribution partners in order to get these ventilator carts to end-users as quickly as possible.”

Because MPE is a single source supplier to many of the world’s most recognized medical device OEMs, their FDA registered operations remain fully operational throughout COVID-19. Their dedicated employees are working overtime to contribute to the fight against the coronavirus.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”